Regional licenses are a successful strategy that allow companies to retain certain territorial rights to their compounds while providing capital to fund development of lead assets.
Ironwood is a good example of successfully attaining separate US, EU and Japan regional licenses, maximizing full value of their lead compound, without having to build a commercial business.
Private European companies have been active in searching for great compounds in development with novel science.
Asian carve out strategies are still popular, allowing companies to receive upfront payments to fund development and gain an experienced partner to help with Asian regulatory agencies. Geller Biopharm has strong relationships with both Japanese and Korean companies seeking licenses.
Eastern European licensing strategies are attractive options in adding value to assets that would normally not be marketed actively, however, due to regulatory constraints, can only be pursued once the compound is in registration with the FDA/EMEA.